CytomX Therapeutics Receives $70,000,000 Series D Financing
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4a5fea5b-10d5-45b9-bb48-9c07aee1f37f
Date 6/17/2015
Company Name CytomX Therapeutics
Mailing Address 343 Oyster Point Blvd. South San Francisco, CA 94080 USA
Company Description CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodies, proteolytically-activated antibodies.
Proceeds Purposes Proceeds from the financing will support the continued advancement of CytomX’s pipeline of Probody therapeutics toward clinical studies, including a Precision cancer immunotherapy directed against PD-L1 and Probody drug conjugates against novel, first in class targets. The financing will also support the expansion of Probody research and development activities in the areas of T-cell agonists, bispecific antibodies and engineered T-cell therapies.